Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.
With an increasingly aged population, many patients will present with diffuse large B-cell lymphoma in their 70s and 80s. Recently, several randomized studies have confirmed the benefit of rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and showed a substantial improvement in the outcome of fit elderly patients. This article reviews the efficacy and toxicity of the current treatment regimens applied for the treatment of diffuse large B-cell lymphoma in elderly patients and provides practical recommendations for the management of these patients.
|Keywords||Aged, aging, antineoplastic agent, comorbidity, female, geriatrics, human, large cell lymphoma, male, methodology, monoclonal antibody, oncology, palliative, rituximab|
|Persistent URL||dx.doi.org/10.1007/s11912-008-0063-2, hdl.handle.net/1765/14300|
Lugtenburg, P.J, & Sonneveld, P. (2008). Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.. Current Oncology Reports (Print), 10(5), 412–419. doi:10.1007/s11912-008-0063-2